A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance

Julia S. Samaddar, Virgil T. Gaddy, Jennifer Duplantier, Sudharsan Periyasamy Thandavan, Manish Shah, Marlena J. Smith, Darren Browning, Jim Rawson, Sylvia B. Smith, John T. Barrett, Patricia V. Schoenlein

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

This study identifies macroautophagy as a key mechanism of cell survival in estrogen receptor-positive (ER+) breast cancer cells undergoing treatment with 4-hydroxytamoxifen (4-OHT). This selective ER modifier is an active metabolite of tamoxifen commonly used for the treatment of breast cancer. Our study provides the following key findings: (a) only 20% to 25% of breast cancer cells treated with 4-OHT in vitro die via caspase-dependent cell death; more typically, the antiestrogen-treated ER+ breast cancer cells express increased levels of macroautophagy and are viable; (b) 4-OHT-induced cell death, but not 4-OHT-induced macroautophagy, can be blocked by the pan-caspase inhibitor z-VAD-fmk, providing strong evidence that these two outcomes of antiestrogen treatment are not linked in an obligatory manner; (c) 4-OHT-resistant cells selected from ER+ breast cancer cells show an increased ability to undergo antiestrogen-induced macroautophagy without induction of caspase-dependent cell death; and (d) 4-OHT, when used in combination with inhibitors of autophagosome function, induces robust, caspase-dependent apoptosis of ER+, 4-OHT-resistant breast cancer cells. To our knowledge, these studies provide the first evidence that macroautophagy plays a critical role in the development of antiestrogen resistance. We propose that targeting autophagosome function will improve the efficacy of hormonal treatment of ER+ breast cancer.

Original languageEnglish (US)
Pages (from-to)2977-2987
Number of pages11
JournalMolecular cancer therapeutics
Volume7
Issue number9
DOIs
StatePublished - Oct 22 2008

Fingerprint

Estrogen Receptor Modulators
Autophagy
Cell Death
Breast Neoplasms
Caspases
Caspase Inhibitors
Tamoxifen
afimoxifene
4,17 beta-dihydroxy-4-androstene-3-one
Estrogen Receptors
Cell Survival
Apoptosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. / Samaddar, Julia S.; Gaddy, Virgil T.; Duplantier, Jennifer; Thandavan, Sudharsan Periyasamy; Shah, Manish; Smith, Marlena J.; Browning, Darren; Rawson, Jim; Smith, Sylvia B.; Barrett, John T.; Schoenlein, Patricia V.

In: Molecular cancer therapeutics, Vol. 7, No. 9, 22.10.2008, p. 2977-2987.

Research output: Contribution to journalArticle

@article{a0f9d8dad63242228ec867cc6397e7ac,
title = "A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance",
abstract = "This study identifies macroautophagy as a key mechanism of cell survival in estrogen receptor-positive (ER+) breast cancer cells undergoing treatment with 4-hydroxytamoxifen (4-OHT). This selective ER modifier is an active metabolite of tamoxifen commonly used for the treatment of breast cancer. Our study provides the following key findings: (a) only 20{\%} to 25{\%} of breast cancer cells treated with 4-OHT in vitro die via caspase-dependent cell death; more typically, the antiestrogen-treated ER+ breast cancer cells express increased levels of macroautophagy and are viable; (b) 4-OHT-induced cell death, but not 4-OHT-induced macroautophagy, can be blocked by the pan-caspase inhibitor z-VAD-fmk, providing strong evidence that these two outcomes of antiestrogen treatment are not linked in an obligatory manner; (c) 4-OHT-resistant cells selected from ER+ breast cancer cells show an increased ability to undergo antiestrogen-induced macroautophagy without induction of caspase-dependent cell death; and (d) 4-OHT, when used in combination with inhibitors of autophagosome function, induces robust, caspase-dependent apoptosis of ER+, 4-OHT-resistant breast cancer cells. To our knowledge, these studies provide the first evidence that macroautophagy plays a critical role in the development of antiestrogen resistance. We propose that targeting autophagosome function will improve the efficacy of hormonal treatment of ER+ breast cancer.",
author = "Samaddar, {Julia S.} and Gaddy, {Virgil T.} and Jennifer Duplantier and Thandavan, {Sudharsan Periyasamy} and Manish Shah and Smith, {Marlena J.} and Darren Browning and Jim Rawson and Smith, {Sylvia B.} and Barrett, {John T.} and Schoenlein, {Patricia V.}",
year = "2008",
month = "10",
day = "22",
doi = "10.1158/1535-7163.MCT-08-0447",
language = "English (US)",
volume = "7",
pages = "2977--2987",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance

AU - Samaddar, Julia S.

AU - Gaddy, Virgil T.

AU - Duplantier, Jennifer

AU - Thandavan, Sudharsan Periyasamy

AU - Shah, Manish

AU - Smith, Marlena J.

AU - Browning, Darren

AU - Rawson, Jim

AU - Smith, Sylvia B.

AU - Barrett, John T.

AU - Schoenlein, Patricia V.

PY - 2008/10/22

Y1 - 2008/10/22

N2 - This study identifies macroautophagy as a key mechanism of cell survival in estrogen receptor-positive (ER+) breast cancer cells undergoing treatment with 4-hydroxytamoxifen (4-OHT). This selective ER modifier is an active metabolite of tamoxifen commonly used for the treatment of breast cancer. Our study provides the following key findings: (a) only 20% to 25% of breast cancer cells treated with 4-OHT in vitro die via caspase-dependent cell death; more typically, the antiestrogen-treated ER+ breast cancer cells express increased levels of macroautophagy and are viable; (b) 4-OHT-induced cell death, but not 4-OHT-induced macroautophagy, can be blocked by the pan-caspase inhibitor z-VAD-fmk, providing strong evidence that these two outcomes of antiestrogen treatment are not linked in an obligatory manner; (c) 4-OHT-resistant cells selected from ER+ breast cancer cells show an increased ability to undergo antiestrogen-induced macroautophagy without induction of caspase-dependent cell death; and (d) 4-OHT, when used in combination with inhibitors of autophagosome function, induces robust, caspase-dependent apoptosis of ER+, 4-OHT-resistant breast cancer cells. To our knowledge, these studies provide the first evidence that macroautophagy plays a critical role in the development of antiestrogen resistance. We propose that targeting autophagosome function will improve the efficacy of hormonal treatment of ER+ breast cancer.

AB - This study identifies macroautophagy as a key mechanism of cell survival in estrogen receptor-positive (ER+) breast cancer cells undergoing treatment with 4-hydroxytamoxifen (4-OHT). This selective ER modifier is an active metabolite of tamoxifen commonly used for the treatment of breast cancer. Our study provides the following key findings: (a) only 20% to 25% of breast cancer cells treated with 4-OHT in vitro die via caspase-dependent cell death; more typically, the antiestrogen-treated ER+ breast cancer cells express increased levels of macroautophagy and are viable; (b) 4-OHT-induced cell death, but not 4-OHT-induced macroautophagy, can be blocked by the pan-caspase inhibitor z-VAD-fmk, providing strong evidence that these two outcomes of antiestrogen treatment are not linked in an obligatory manner; (c) 4-OHT-resistant cells selected from ER+ breast cancer cells show an increased ability to undergo antiestrogen-induced macroautophagy without induction of caspase-dependent cell death; and (d) 4-OHT, when used in combination with inhibitors of autophagosome function, induces robust, caspase-dependent apoptosis of ER+, 4-OHT-resistant breast cancer cells. To our knowledge, these studies provide the first evidence that macroautophagy plays a critical role in the development of antiestrogen resistance. We propose that targeting autophagosome function will improve the efficacy of hormonal treatment of ER+ breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=54049151248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049151248&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-08-0447

DO - 10.1158/1535-7163.MCT-08-0447

M3 - Article

C2 - 18790778

AN - SCOPUS:54049151248

VL - 7

SP - 2977

EP - 2987

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 9

ER -